Claims for Patent: 10,513,737
✉ Email this page to a colleague
Summary for Patent: 10,513,737
Title: | Cancer diagnostics using non-coding transcripts |
Abstract: | Disclosed herein, in certain instances, are methods for the diagnosis, prognosis and determination of cancer progression of a cancer in a subject. Further disclosed herein, in certain instances, are methods for determining the treatment modality of a cancer in a subject. The methods comprise expression-based analysis of non-coding targets and coding targets. Further disclosed herein, in certain instances, are probe sets for use in assessing a cancer status in a subject. |
Inventor(s): | Davicioni; Elai (La Jolla, CA), Erho; Nicholas George (Vancouver, CA), Vergara Correa; Ismael A. (West Vancouver, CA) |
Assignee: | DECIPHER BIOSCIENCES, INC. (San Diego, CA) |
Application Number: | 14/365,085 |
Patent Claims: | 1. A method of treating prostate cancer in a subject, comprising: (a) obtaining or having obtained an expression level in a sample from a subject for a plurality of targets,
wherein the plurality of targets comprises at least two targets selected from the group consisting of SEQ ID NOs: 103, 218, 275, 301, 321, 607, 707, 795, 828 and 832; (b) determining that the subject is at risk of developing metastatic prostate cancer
based on said expression level, or determining that the subject is not at risk of developing metastatic prostate cancer based on said expression level; and (c) administering a prostate cancer treatment to the subject if the subject is determined to be
at risk of developing metastatic prostate cancer based on said expression level, or monitoring without administering the prostate cancer treatment to the subject if the subject is determined to not be at risk of developing metastatic prostate cancer
based on said expression level.
2. The method of claim 1, wherein the treatment is selected from the group consisting of surgery, a chemotherapeutic agent, radiation therapy, a biological therapeutic, cancer vaccine, gene therapy or a combination thereof. 3. The method of claim 2, wherein the treatment is prostatectomy, a chemotherapeutic agent, anti-androgen therapy or a combination thereof. 4. The method of claim 1, wherein the sample is selected from the group consisting of tissue, blood, plasma, serum, urine, a urine supernatant, a urine cell pellet, semen, prostatic secretions and prostate cells. 5. The method of claim 1, wherein said obtaining comprises a method selected from the group consisting of a sequencing technique, a nucleic acid hybridization technique, and nucleic acid amplification technique, and an immunoassay. 6. The method of claim 5, wherein the nucleic acid amplification technique is polymerase chain reaction, reverse transcription polymerase chain reaction, transcription-mediated amplification, ligase chain reaction, strand displacement amplification or nucleic acid sequence-based amplification. 7. The method of claim 1, wherein administering a prostate cancer treatment comprises administering cisplatin, carboplatin, oxaliplatin, mechlorethamine, cyclophosphamide, chlorambucil, ifosfamide, vincristine, vinblastine, vinorelbine, vindesine, paclitaxel, docetaxel, podophyllotoxin, irinotecan, topotecan, amsacrine, etoposide, etoposide phosphate, teniposide, actinomycin, anthracyclines, doxorubicin, daunorubicin, valrubicin, idarubicin, epirubicin, bleomycin, plicamycin, mitomycin, tositumomab, samarium-153-lexidronam, strontium-89 chloride, interferon alpha, interferon beta, interferon gamma, interleukin-2, interleukin 7, interleukin 12, G-CSF, GM-CSF, rituximab, trastuzumab, bacillus Calmette-Guerin (BCG), levamisole, porfimer sodium, mitoxantrone, prednisone, samarium, strontium, finasteride, or dutasteride. |
Details for Patent 10,513,737
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Teknika Llc | TICE BCG | bcg live | For Injection | 102821 | 06/21/1989 | ⤷ Try a Trial | 2031-12-13 |
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2031-12-13 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2031-12-13 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2031-12-13 |
Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | 06/22/2017 | ⤷ Try a Trial | 2031-12-13 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2031-12-13 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.